FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917152313> ?p ?o ?g. }

• W2917152313 endingPage "e502" @default.
• W2917152313 startingPage "e492" @default.
• W2917152313 abstract "BackgroundNovartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first country to receive the programme.MethodsWe did a cluster-randomised controlled trial in eight counties in Kenya. Counties (clusters) were randomly assigned to the intervention or the control group with a covariate-constrained randomisation procedure that maximised balance on a set of demographic and health variables. In intervention counties, public and non-profit health facilities were allowed to purchase Novartis Access medicines from the Mission for Essential Drugs and Supplies (MEDS). Data were collected from all facilities served by MEDS and a sample of households in study counties. Households were eligible if they had at least one adult patient who had been diagnosed and prescribed medicines for one of the non-communicable diseases targeted by the programme: hypertension, heart failure, dyslipidaemia, type 2 diabetes, asthma, or breast cancer. Primary outcomes were availability and price of portfolio medicines at health facilities, irrespective of brand; and availability of medicines at patient households. Impacts were estimated with intention-to-treat analysis. This trial is registered with ClinicalTrials.gov (NCT02773095).FindingsOn March 8, 2016, we randomly assigned eight clusters to intervention (four clusters; 74 health facilities; 342 patients) or control (four clusters; 63 health facilities; 297 patients). 69 intervention and 58 control health facilities, and 306 intervention and 265 control patients were evaluated after a 15 month intervention period (last visit February 28, 2018). Novartis Access significantly increased the availability of amlodipine (adjusted odds ratio [aOR] 2·84, 95% CI 1·10 to 7·37; p=0·031) and metformin (aOR 4·78, 95% CI 1·44 to 15·86; p=0·011) at health facilities, but did not affect the availability of portfolio medicines overall (adjusted β [aβ] 0·05, 95% CI −0·01 to 0·10; p=0·096) or their price (aβ 0·48, 95% CI −1·12 to 0·72; p=0·500). The programme did not affect medicine availability at patient households (aOR 0·83, 95% CI 0·44 to 1·57; p=0·569).InterpretationNovartis Access had little effect in its first year in Kenya. Access programmes operate within complex health systems and reducing the wholesale price of medicines might not always or immediately translate to improved patient access. The evidence generated by this study will inform Novartis's efforts to improve their programme going forward. The study also contributes to the public evidence base on strategies for improving access to medicines globally.FundingSandoz International (a subsidiary of Novartis International). Novartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first country to receive the programme. We did a cluster-randomised controlled trial in eight counties in Kenya. Counties (clusters) were randomly assigned to the intervention or the control group with a covariate-constrained randomisation procedure that maximised balance on a set of demographic and health variables. In intervention counties, public and non-profit health facilities were allowed to purchase Novartis Access medicines from the Mission for Essential Drugs and Supplies (MEDS). Data were collected from all facilities served by MEDS and a sample of households in study counties. Households were eligible if they had at least one adult patient who had been diagnosed and prescribed medicines for one of the non-communicable diseases targeted by the programme: hypertension, heart failure, dyslipidaemia, type 2 diabetes, asthma, or breast cancer. Primary outcomes were availability and price of portfolio medicines at health facilities, irrespective of brand; and availability of medicines at patient households. Impacts were estimated with intention-to-treat analysis. This trial is registered with ClinicalTrials.gov (NCT02773095). On March 8, 2016, we randomly assigned eight clusters to intervention (four clusters; 74 health facilities; 342 patients) or control (four clusters; 63 health facilities; 297 patients). 69 intervention and 58 control health facilities, and 306 intervention and 265 control patients were evaluated after a 15 month intervention period (last visit February 28, 2018). Novartis Access significantly increased the availability of amlodipine (adjusted odds ratio [aOR] 2·84, 95% CI 1·10 to 7·37; p=0·031) and metformin (aOR 4·78, 95% CI 1·44 to 15·86; p=0·011) at health facilities, but did not affect the availability of portfolio medicines overall (adjusted β [aβ] 0·05, 95% CI −0·01 to 0·10; p=0·096) or their price (aβ 0·48, 95% CI −1·12 to 0·72; p=0·500). The programme did not affect medicine availability at patient households (aOR 0·83, 95% CI 0·44 to 1·57; p=0·569). Novartis Access had little effect in its first year in Kenya. Access programmes operate within complex health systems and reducing the wholesale price of medicines might not always or immediately translate to improved patient access. The evidence generated by this study will inform Novartis's efforts to improve their programme going forward. The study also contributes to the public evidence base on strategies for improving access to medicines globally." @default.
• W2917152313 created "2019-03-02" @default.
• W2917152313 creator A5007676709 @default.
• W2917152313 creator A5021601421 @default.
• W2917152313 creator A5026122446 @default.
• W2917152313 creator A5032060371 @default.
• W2917152313 creator A5046099014 @default.
• W2917152313 creator A5088242821 @default.
• W2917152313 date "2019-04-01" @default.
• W2917152313 modified "2023-10-15" @default.
• W2917152313 title "Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial" @default.
• W2917152313 cites W1815444468 @default.
• W2917152313 cites W2076489890 @default.
• W2917152313 cites W2122501553 @default.
• W2917152313 cites W2129733505 @default.
• W2917152313 cites W2132816662 @default.
• W2917152313 cites W2136309299 @default.
• W2917152313 cites W2138490742 @default.
• W2917152313 cites W2164621115 @default.
• W2917152313 cites W2172131969 @default.
• W2917152313 cites W2554416008 @default.
• W2917152313 cites W2556311538 @default.
• W2917152313 cites W2604111346 @default.
• W2917152313 cites W2801640067 @default.
• W2917152313 cites W2805448345 @default.
• W2917152313 cites W2807147335 @default.
• W2917152313 cites W2807666056 @default.
• W2917152313 cites W2810694128 @default.
• W2917152313 cites W2892328687 @default.
• W2917152313 cites W2898136826 @default.
• W2917152313 doi "https://doi.org/10.1016/s2214-109x(18)30563-1" @default.
• W2917152313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30799142" @default.
• W2917152313 hasPublicationYear "2019" @default.
• W2917152313 type Work @default.
• W2917152313 sameAs 2917152313 @default.
• W2917152313 citedByCount "35" @default.
• W2917152313 countsByYear W29171523132019 @default.
• W2917152313 countsByYear W29171523132020 @default.
• W2917152313 countsByYear W29171523132021 @default.
• W2917152313 countsByYear W29171523132022 @default.
• W2917152313 countsByYear W29171523132023 @default.
• W2917152313 crossrefType "journal-article" @default.
• W2917152313 hasAuthorship W2917152313A5007676709 @default.
• W2917152313 hasAuthorship W2917152313A5021601421 @default.
• W2917152313 hasAuthorship W2917152313A5026122446 @default.
• W2917152313 hasAuthorship W2917152313A5032060371 @default.
• W2917152313 hasAuthorship W2917152313A5046099014 @default.
• W2917152313 hasAuthorship W2917152313A5088242821 @default.
• W2917152313 hasBestOaLocation W29171523131 @default.
• W2917152313 hasConcept C118552586 @default.
• W2917152313 hasConcept C138816342 @default.
• W2917152313 hasConcept C141071460 @default.
• W2917152313 hasConcept C159110408 @default.
• W2917152313 hasConcept C164866538 @default.
• W2917152313 hasConcept C168563851 @default.
• W2917152313 hasConcept C176400912 @default.
• W2917152313 hasConcept C199360897 @default.
• W2917152313 hasConcept C2780665704 @default.
• W2917152313 hasConcept C41008148 @default.
• W2917152313 hasConcept C512399662 @default.
• W2917152313 hasConcept C71924100 @default.
• W2917152313 hasConcept C99454951 @default.
• W2917152313 hasConceptScore W2917152313C118552586 @default.
• W2917152313 hasConceptScore W2917152313C138816342 @default.
• W2917152313 hasConceptScore W2917152313C141071460 @default.
• W2917152313 hasConceptScore W2917152313C159110408 @default.
• W2917152313 hasConceptScore W2917152313C164866538 @default.
• W2917152313 hasConceptScore W2917152313C168563851 @default.
• W2917152313 hasConceptScore W2917152313C176400912 @default.
• W2917152313 hasConceptScore W2917152313C199360897 @default.
• W2917152313 hasConceptScore W2917152313C2780665704 @default.
• W2917152313 hasConceptScore W2917152313C41008148 @default.
• W2917152313 hasConceptScore W2917152313C512399662 @default.
• W2917152313 hasConceptScore W2917152313C71924100 @default.
• W2917152313 hasConceptScore W2917152313C99454951 @default.
• W2917152313 hasIssue "4" @default.
• W2917152313 hasLocation W29171523131 @default.
• W2917152313 hasLocation W29171523132 @default.
• W2917152313 hasLocation W29171523133 @default.
• W2917152313 hasLocation W29171523134 @default.
• W2917152313 hasOpenAccess W2917152313 @default.
• W2917152313 hasPrimaryLocation W29171523131 @default.
• W2917152313 hasRelatedWork W1919754041 @default.
• W2917152313 hasRelatedWork W1965851575 @default.
• W2917152313 hasRelatedWork W1990983629 @default.
• W2917152313 hasRelatedWork W2016938551 @default.
• W2917152313 hasRelatedWork W2408996308 @default.
• W2917152313 hasRelatedWork W2743111491 @default.
• W2917152313 hasRelatedWork W2953510858 @default.
• W2917152313 hasRelatedWork W2989932918 @default.
• W2917152313 hasRelatedWork W3126475310 @default.
• W2917152313 hasRelatedWork W4318269825 @default.
• W2917152313 hasVolume "7" @default.
• W2917152313 isParatext "false" @default.
• W2917152313 isRetracted "false" @default.
• W2917152313 magId "2917152313" @default.
• W2917152313 workType "article" @default.